Investment Criteria


  • $300 – $800 million equity investment per transaction.
  • Moderate use of leverage
  • Majority ownership with management participation
  • Return objective consistent with strategic rather than financial buyers
  • No turnaround or distressed assets

Industry/ Markets

  • Growth industries with positive, long-term underlying macro trends and drivers.
  • Attractive competitive dynamics
  • Sectors of focus include healthcare, technology, advanced industrial, business services.

Company- Specific

  • Revenues > $50 million
  • Sustainable long-term organic growth profile
  • Proven, strong structural/unit economic profitability
  • Cash flow positive preferred today, required over time
  • US or Nordic headquarters
  • Platform businesses with proven business model
  • Sustainable competitive advantage (e.g. brand power, technology differentiation, high switching costs)


Value Proposition

  • Long-term focus on value creation and indefinite holding period
  • Low reliance on leverage
  • Global network of companies and people
  • Strong capital base to support growth initiatives (both organic and M&A)
  • Established, highly — referenceable investor with strong reputation and track record of success

For Owners/Seller

  • Price competitive given long-term holding period and approach to value
  • Streamlined process with no financing contingencies
  • Reputation for integrity and transparency

For Management

  • Strong operating flexibility enabled by capital depth, moderate leverage, and long holding horizon.
    • Management incentive plan allowing management to share in value creation at predefined exit windows
    • Ability to invest in value-creating initiatives
    • Opportunity to pursue strategic transactions
  • Minimal process distraction to management — continuous focus on value maximization
  • Global network of Investor AB and Wallenberg family contacts.

Case Studies

view all

Aptalis Pharma

Aptalis Pharma is a leading specialty pharmaceutical company providing innovative therapies for unmet medical needs, including gastrointestinal disorders and cystic fibrosis.

Read The Case Study

BlueArc Corporation

BlueArc is a provider of scalable, high performance, network storage systems for the enterprise and data intensive markets, such as electronic discovery, entertainment, internet services and life sciences.

Read The Case Study

Ception Therapeutics

When Investor Growth Capital first invested, Ception Therapeutics was a development-stage biopharmaceutical company focused on inflammatory diseases.

Read The Case Study